EUVIMEDEUVIMED entdecken
Multizentrische Studie

Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study

Xiaozhi Chen, Hangkuan Liu, Linjie Li, Geru A, Pengfei Sun, Doreen Su-Yin Tan, Mark Yan-Yee Chan, Roger Sik-Yin Foo, Gregg C Fonarow, Qing Yang, Xin Zhou

Clinical Research in Cardiology · 2025-06 · 114 (6) · 796-808

DOI: 10.1007/s00392-025-02645-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 10.04.2025. Verfasst von Xiaozhi Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Medical University General Hospital, Tianjin Medical University, 154, Anshan Road, Heping District, Tianjin, 300052…. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Atorvastatin, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Key Medical Discipline (Specialty) Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Statins are associated with liver-related adverse events, with risk varying by statin type. However, current guidelines lack specific recommendations for statin selection in acute myocardial infarction (AMI) patients with elevated liver enzymes. METHODS: This cohort study used a target trial emulation approach to include AMI patients treated with percutaneous coronary intervention between 2013 and 2022 from the Tianjin Health and Medical Data Platform, China. Eligible patients with atorvastatin or rosuvastatin prescriptions during hospitalization were matched 1:1 using propensity scores in those with elevated liver enzymes and normal liver enzymes respectively, and tracked for 1 year or until death (intention-to-treat analysis). Nonadherent patients were censored in the per-protocol analysis. The primary outcome was 1-year all-cause mortality, with secondary outcomes including recurrent MI and stroke. RESULTS: In a matched cohort of 25,728 patients with elevated liver enzymes, 614 deaths (2.4%) occurred. Atorvastatin was associated with higher all-cause mortality compared to rosuvastatin (hazard ratio [HR]: 1.29, 95% confidence interval [CI] 1.10-1.51), consistent in the per-protocol analysis, and the in-hospital mortality difference was confirmed in an independent cohort. No significant differences were observed for recurrent MI (HR: 0.98, 95% CI 0.87-1.11) or stroke (HR: 1.10, 95% CI 0.93-1.28). Similar target trial emulation design among 18,270 AMI patients with normal liver enzymes at admission (9135 per group) found no significant differences between the two statins in all-cause mortality (HR: 1.09, 95% CI 0.88-1.35), recurrent MI (HR: 1.05, 95% CI 0.90-1.23), or stroke (HR: 1.07, 95% CI 0.90-1.28). CONCLUSIONS: Atorvastatin treatment was associated with a higher risk of 1-year all-cause mortality than Rosuvastatin in a target trial emulation study of patients with elevated liver enzymes following AMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rosuvastatin CalciumAtorvastatinMyocardial InfarctionPercutaneous Coronary InterventionHumansMaleFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsAgedMiddle AgedChinaHospital MortalityTreatment OutcomeCause of Death

Stichwörter der Autor:innen

AtorvastatinElevated liver enzymesMortalityMyocardial infarctionRosuvastatin

Substanzen

Rosuvastatin CalciumAtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Tianjin Medical University General Hospital, Tianjin Medical University, 154, Anshan Road, Heping District, Tianjin, 300052, China.
  • Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore.
  • Department of Cardiology, National University Heart Centre, 5 Lower Kent Ridge Rd, Singapore, 119074, Singapore.
  • Cardiovascular Research Institute, National University Health System, 14 Medical Drive, Singapore, 117599, Singapore.
  • Yong Loo-Lin School of Medicine, National University of Singapore, 1E, Kent, Ridge Road, Singapore, 119228, Singapore.
  • Division of Cardiology, David Geffen School of Medicine, University of California, Geffen Hall 885 Tiverton Drive, Los Angeles, CA, 90095, USA.

Förderung

  • National Natural Science Foundation of China
  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Chen, X., Liu, H., Li, L., A, G., Sun, P., Tan, D. S., Chan, M. Y., Foo, R. S., Fonarow, G. C., Yang, Q., & Zhou, X. (2025). Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study. Clinical Research in Cardiology, 114(6), 796-808. https://doi.org/10.1007/s00392-025-02645-0

Vancouver

Chen X, Liu H, Li L, A G, Sun P, Tan DS, et al. Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study. Clinical Research in Cardiology. 2025;114(6):796-808. doi:10.1007/s00392-025-02645-0

BibTeX
@article{Chen2025,
  author = {Chen, Xiaozhi and Liu, Hangkuan and Li, Linjie and A, Geru and Sun, Pengfei and Tan, Doreen Su-Yin and Chan, Mark Yan-Yee and Foo, Roger Sik-Yin and Fonarow, Gregg C and Yang, Qing and Zhou, Xin},
  title = {Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  volume = {114},
  number = {6},
  pages = {796--808},
  doi = {10.1007/s00392-025-02645-0}
}
Kostenlos starten →